



04

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>A61K 39/00, 41/00, C12N 5/00 // (A61K 39/00, 31:40)</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 00/54802</b> <b>(43) International Publication Date:</b> 21 September 2000 (21.09.00)
<b>(21) International Application Number:</b> PCT/GB00/00903 <b>(22) International Filing Date:</b> 10 March 2000 (10.03.00) <b>(30) Priority Data:</b> 9905911.5 15 March 1999 (15.03.99) GB <b>(71) Applicant (for all designated States except US):</b> PHOTOCURE ASA [NO/NO]; Montebello, P.O. Box 55, N-0310 Oslo (NO). <b>(71) Applicant (for GB only):</b> JONES, Elizabeth, Louise [GB/GB]; Frank B. Dehn & Co., 179 Queen Victoria Street, London EC4V 4EL (GB). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> BERG, Kristian [NO/NO]; Vollenveien 158, N-1389 Heggedal (NO). TJELLE, Torunn, E. [NO/NO]; Seterliveien 1, N-1162 Oslo (NO). HOGSET, Anders [NO/NO]; Treskeveien 32A, N-0681 Oslo (NO). PRASMICKAITE, Lina [NO/NO]; St. Edmundsvei 39D, N-0280 Oslo (NO). <b>(74) Agents:</b> JONES, Elizabeth, Louise et al.; Frank B. Dehn & Co., 179 Queen Victoria Street, London EC4V 4EL (GB).		<b>(81) Designated States:</b> AE, AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), DM, DZ, EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KR (Utility model), KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> METHOD  <b>(57) Abstract</b>  <p>The present invention provides a method of expressing an antigenic molecule or a part thereof on the surface of an antigen-presenting cell, said method comprising introducing a molecule into the cell cytosol by photochemical internalisation, wherein said molecule, or a part thereof, is subsequently presented on the surface of said cell. Methods of vaccination comprising this method, together with compositions comprising said cells and uses involving said cells expressing antigenic molecules are also provided.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

### METHOD

5 The present invention relates to a method of vaccination which involves using photodynamic treatment (PDT) to introduce vaccine components into cells to achieve antigen presentation, and to vaccine compositions useful in such a method.

10 The majority of molecules do not readily penetrate cell membranes. Methods for introducing molecules into the cytosol of living cells are useful tools for manipulating and studying biological processes. Among the most commonly used methods today are microinjection, red blood cell ghost-mediated fusion and liposome  
15 fusion, osmotic lysis of pinosomes, scrape loading, electroporation, calcium phosphate and virus-mediated transfection. These techniques are useful for investigating cells in culture, although in many cases they may be impractical, time consuming, inefficient or  
20 they may induce significant cell death. Thus such techniques are not optimal for use in biological or medical research, or in therapies, where it is required that cells should remain viable and/or functional.

25 It is well known that porphyrins and many other photosensitizing compounds may induce cytotoxic effects on cells and tissues. These effects are based upon the fact that upon exposure to light the photosensitizing compound may become toxic or may release toxic substances such as singlet O or other oxidising radicals  
30 which are damaging to cellular material or biomolecules, including the membranes of cells and cell structures, and such cellular or membrane damage may eventually kill the cells. These effects have been utilised in the treatment of various abnormalities or disorders,  
35 including especially neoplastic diseases. The treatment is named photodynamic therapy (PDT) and involves the administration of photosensitizing

(photochemotherapeutic) agents to the affected area of the body, followed by exposure to photoactivating light in order to activate the photosensitizing agents and convert them into cytotoxic form, whereby the affected cells are killed or their proliferative potential diminished. Photosensitizing agents are known which will localise preferentially or selectively to the desired target site e.g. to a tumour or other lesion.

A range of photosensitizing agents are known, including notably the psoralens, the porphyrins, the chlorins and the phthalocyanins. Such drugs become toxic when exposed to light.

Photosensitizing drugs may exert their effects by a variety of mechanisms, directly or indirectly. Thus for example, certain photosensitisers become directly toxic when activated by light, whereas others act to generate toxic species, e.g. oxidising agents such as singlet oxygen or other oxygen-derived free radicals, which are extremely destructive to cellular material and biomolecules such as lipids, proteins and nucleic acids.

Porphyrin photosensitisers act indirectly by generation of toxic oxygen species, and are regarded as particularly favourable candidates for PDT. Porphyrins are naturally occurring precursors in the synthesis of heme. In particular, heme is produced when iron ( $\text{Fe}^{2+}$ ) is incorporated in protoporphyrin IX (Pp) by the action of the enzyme ferrochelatase. Pp is an extremely potent photosensitizer, whereas heme has no photosensitizing effect. A variety of porphyrin-based or porphyrin-related photosensitisers are known in the art and described in the literature.

The cytotoxic effect is mediated mainly through the formation of singlet oxygen. This reactive intermediate has a very short lifetime in cells ( $<0.04 \mu\text{s}$ ). Thus, the primary cytotoxic effect of PDT is executed during light exposure and very close to the sites of formation of  $^1\text{O}_2$ .  $^1\text{O}_2$  reacts with and oxidizes proteins (histidine,

tryptophan, methionine, cysteine, tyrosine), DNA (guanine), unsaturated fatty acids and cholesterol. One of the advantages of PDT is that tissues unexposed to light may be left unaffected ie. that a selective PDT effect may be obtained. There is extensive documentation regarding use of PDT to destroy unwanted cell populations, for example neoplastic cells. The patent literature describes a number of photodynamic compounds, alone or conjugated with targeting agents, e.g. immunoglobulins directed to neoplastic cell receptor determinants, making the complex more cell specific. Certain photochemical compounds, such as hematoporphyrin derivatives, have furthermore an inherent ability to localise in malignant cells. Such methods and compounds, are described in the Norwegian patent NO 173319, in Norwegian patent applications Nos. 90 0731, 176 645, 176 947, 180 742, 176 786, 301 981, 30 0499 and 89 1491.

In WO93/14142 a drug delivery system is described which comprises an anti-cancer agent and a photoactivatable agent (ie. a photosensitizer) attached to copolymeric carriers. Upon administration this complex enters the cell interior by pinocytosis or phagocytosis and locates inside the endosomes and lysosomes. In the lysosomes, the bond between the anti-neoplastic agent and the polymer is hydrolysed and the former can diffuse passively through the lysosome membrane into the cytosol. The utility of this method is thus limited to small molecular compounds which are able to diffuse across the lysosome membranes. After allowing a time lag for diffusion, a light source of appropriate wavelength and energy is applied to activate the photo-activatable compound. The combined effect of the anti-cancer agent and photoactivatable agent destroy the cell.

Such PDT methods as described above are thus directed to the destruction of cell structures leading

to cell death.

WO 96/07432, on the other hand, is concerned with methods which use the photodynamic effect as a mechanism for introducing otherwise membrane-impermeable molecules into the cytosol of a cell in a manner which does not result in widespread cell destruction or cell death. In this method, the molecule is co-internalised (more particularly "endocytosed") into an intracellular vesicle in the cell (e.g. a lysosome or endosome) together with a photosensitizing agent. The cell is then exposed to photoactivating light which "activates" the photosensitizer, which in turn causes the vesicle membrane to disrupt or rupture, releasing the vesicle contents, including the molecule, into the cell interior ie. the cytosol. It was found that in such a method the functionality or the viability of the majority of the cells was not deleteriously affected. Thus, the utility of such a method, termed "photochemical internalisation" was proposed for transporting a variety of different molecules, including therapeutic agents, into the cytosol ie. into the interior of a cell.

We have now found that such a method can advantageously be used, not only to transfer molecules in the interior of a cell, but also to present or express them on a cell surface. Thus, following transport and release of a molecule into the cell cytosol, it may be transported to the surface of the cell where it may be presented on the outside of the cell ie. on the cell surface. Such a method has particular utility in the field of vaccination, where vaccine components ie. antigens or immunogens, may be introduced to a cell for presentation on the surface of that cell, in order to induce, facilitate or augment an immune response.

At its most general, the present invention thus provides a method of expressing an antigenic molecule or a part thereof on the surface of a cell, preferably an

- 5 -

antigen-presenting cell, said method comprising  
introducing a molecule into the cell cytosol by  
photochemical internalisation, wherein said molecule, or  
a part thereof, is subsequently presented on the surface  
5 of said cell.

As used herein "expressing" or "presenting" refers  
to the presence of the molecule or a part thereof on the  
surface of said cell such that at least a portion of  
that molecule is exposed and accessible to the  
10 environment surrounding that cell. Expression on the  
"surface" may be achieved in which the molecule to be  
expressed is in contact with the cell membrane and/or  
components which may be present or caused to be present  
in that membrane.

Such antigenic presentation may advantageously  
result in the stimulation of an immune response,  
preferably an immune response which confers protection  
against subsequent challenge by an entity comprising or  
containing said antigen molecule or part thereof, and  
20 consequently the invention finds particular utility as a  
method of vaccination.

More particularly, this aspect of the invention  
provides a method of expressing an antigenic molecule or  
a part thereof on the surface of a cell, said method  
25 comprising:

contacting said cell with said antigenic molecule  
and with a photosensitizing agent, wherein said molecule  
and said agent are each taken up into an intracellular  
membrane-restricted compartment of said cell; and

30 irradiating said cell with light of a wavelength  
effective to activate the photosensitizing agent, such  
that the membrane of said intracellular compartment is  
disrupted, releasing said molecule into the cytosol of  
the cell, without killing the cell,

35 wherein, said released antigenic molecule, or a  
part thereof, is subsequently presented on the surface  
of said cell.

As used herein, a "disrupted" compartment refers to destruction of the integrity of the membrane of that compartment either permanently or temporarily, sufficient to allow release of the antigenic molecule contained within it.

Alternatively viewed, this aspect of the invention also provides a composition for use in expressing an antigenic molecule or a part thereof on the surface of a cell, preferably to simulate an immune response, said composition comprising an antigenic molecule and a photosensitizing agent. Preferably said composition is pharmaceutically acceptable and contains also a pharmaceutically acceptable excipient or diluent.

In a further aspect, the invention also provides the use of an antigenic molecule and a photosensitizing agent in the preparation of a medicament for use in expressing said antigenic molecule or a part thereof on the surface of a cell to stimulate an immune response.

A still further aspect of the invention provides a product comprising an antigenic molecule and a photosensitizing agent as a combined preparation for simultaneous, separate or sequential use in expressing said antigenic molecule or a part thereof on the surface of a cell, preferably to stimulate an immune response.

A yet further aspect of the invention provides a kit for use in expressing an antigenic molecule or a part thereof on the surface of a cell, said kit comprising

a first container containing said antigenic molecule; and  
a second container containing a photosensitizing agent.

In the invention, the antigenic molecule may be any molecule wherein that molecule or a part thereof is capable of stimulating an immune response, when presented to the immune system in an appropriate manner. Advantageously, therefore the antigenic molecule will be



a vaccine antigen or vaccine component, such as a polypeptide containing entity.

Many such antigens or antigenic vaccine components are known in the art and include all manner of bacterial or viral antigens or indeed antigens or antigenic components of any pathogenic species including protozoa or higher organisms. Whilst traditionally the antigenic components of vaccines have comprised whole organisms (whether live, dead or attenuated) ie. whole cell vaccines, in addition sub-unit vaccines, ie. vaccines based on particular antigenic components of organisms e.g. proteins or peptides, or even carbohydrates, have been widely investigated and reported in the literature. Any such "sub-unit"-based vaccine component may be used as the antigenic molecule of the present invention. However, the invention finds particular utility in the field of peptide vaccines. Thus, a preferred antigenic molecule according to the invention is a peptide (which is defined herein to include peptides of both shorter and longer lengths ie. peptides, oligopeptides or polypeptides, and also protein molecules or fragments thereof e.g. peptides of 5-500 e.g. 10 to 250 such as 15 to 75, or 8 to 25 amino acids). Parts of antigenic molecules which are presented or expressed preferably comprise parts which are generated by antigen-processing machinery within the cell. Parts may however be generated by other means which may be achieved through appropriate antigen design (e.g. pH sensitive bands) or through other cell processing means. Conveniently such parts are of sufficient size to generate an immune response, e.g. in the case of peptides greater than 5, e.g. greater than 10 or 20 amino acids in size.

A vast number of peptide vaccine candidates have been proposed in the literature, for example in the treatment of viral diseases and infections such as AIDS/HIV infection or influenza, canine parvovirus, bovine leukaemia virus, hepatitis, etc. (see e.g. Phanuphak et

al., Asian Pac. J. Allergy. Immunol. 1997, 15(1), 41-8;  
Naruse, Hokkaido Igaku Zasshi 1994, 69(4), 811-20; Casal  
et al., J. Virol., 1995, 69(11), 7274-7; Belyakov et  
al., Proc. Natl. Acad. Sci. USA, 1998, 95(4), 1709-14;  
5 Naruse et al., Proc. Natl. Sci. USA, 1994 91(20), 9588-  
92; Kabeya et al., Vaccine 1996, 14(12), 1118-22; Itoh  
et al., Proc. Natl. Acad. Sci. USA, 1986, 83(23) 9174-8.  
Similarly bacterial peptides may be used, as indeed may  
peptide antigens derived from other organisms or  
10 species.

In addition to antigens derived from pathogenic  
organisms, peptides have also been proposed for use as  
vaccines against cancer or other diseases such as  
multiple sclerosis. For example, mutant oncogene  
15 peptides hold great promise as cancer vaccines acting as  
antigens in the simulation of cytotoxic T-lymphocytes.  
(Schirrmacher, Journal of Cancer Research and Clinical  
Oncology 1995, 121, 443-451; Curtis Cancer Chemotherapy  
and Biological Response Modifiers, 1997, 17, 316-327).  
20 A synthetic peptide vaccine has also been evaluated for  
the treatment of metastatic melanoma (Rosenberg et al.,  
Nat. Med. 1998, 4(3), 321-7). A T-cell receptor peptide  
vaccine for the treatment of multiple sclerosis is  
described in Wilson et al., J. Neuroimmunol. 1997, 76(1-  
25 2), 15-28. Any such peptide vaccine component may be  
used as the antigenic molecule of the invention, as  
indeed may any of the peptides described or proposed as  
peptide vaccines in the literature. The peptide may  
thus be synthetic or isolated or otherwise derived from  
30 an organism.

The cell which is subjected to the methods, uses  
etc. of the invention may be any cell which is capable  
of expressing, or presenting on its surface a molecule  
which is administered or transported into its cytosol.

35 Since the primary utility of the invention resides  
in antigen-presentation or vaccination, the cell is  
conveniently an immune effector cell ie. a cell involved

in the immune response. However, other cells may also present antigen to the immune system and these also fall within the scope of the invention. The cells according to the present invention are thus advantageously antigen-presenting cells. The antigen-presenting cell may be involved in any aspect or "arm" of the immune response, including both humoral and cell-mediated immunity, for example the stimulation of antibody production, or the stimulation of cytotoxic or killer cells, which may recognise and destroy (or otherwise eliminate) cells expressing "foreign" antigens on their surface. The term "stimulating an immune response" thus includes all types of immune responses and mechanisms for stimulating them.

15 The stimulation of cytotoxic cells or antibody-producing cells, requires antigens to be presented to the cell to be stimulated in a particular manner by the antigen-presenting cells, for example MHC Class I presentation (e.g. activation of CD8<sup>+</sup> cytotoxic T-cells requires MHC-1 antigen presentation).

20 Antigen-presenting cells are known in the art and described in the literature and include for example, lymphocytes (both T and B cells), dendritic cells, macrophages etc. Others include for example cancer cells e.g. melanoma cells.

25 For antigen presentation by an antigen-presenting cell to a cytotoxic T-cell (CTL) the antigenic molecule needs to enter the cytosol of the antigen-presenting cell (Germain, Cell, 1994, 76, 287-299). The present invention provides an efficient means of delivery of the antigenic molecule into the cytosol.

30 Once released in the cell cytosol by the photochemical internalisation process, the antigenic molecule may be processed by the antigen-processing machinery of the cell and presented on the cell surface in an appropriate manner e.g. by Class I MHC. This processing may involve degradation of the antigen, e.g.

degradation of a protein or polypeptide antigen into peptides, which peptides are then complexed with molecules of the MHC for presentation. Thus, the antigenic molecule expressed or presented on the surface of the cell according to the present invention may be a part or fragment of the antigenic molecule which is internalised (endocytosed).

Antigens may be taken up by antigen-presenting cells by endocytosis and degraded in the endocytic vesicles to peptides. These peptides may bind to MHC class II molecules in the endosomes and be transported to the cell surface where the peptide-MHC class II complex may be recognised by CD4+ T helper cells and induce an immune response. Alternatively, proteins in the cytosol may be degraded, e.g. by proteasomes and transported into endoplasmic reticulum by means of TAP (transporter associated with antigen presentation) where the peptides may bind to MHC class I molecules and be transported to the cell surface as illustrated in the figure 1 (Yewdell and Bennink, 1992, Adv. Immunol. 52: 1-123). If the peptide is of foreign antigen origin, the peptide-MHC class I complex will be recognised by CD8+ cytotoxic T-cells (CTLs). The CTLs will bind to the peptide-MHC (HLA) class I complex and thereby be activated, start to proliferate and form a clone of CTLs. The target cell and other target cells with the same peptide-MHC class I complex on the cells surface may be killed by the CTL clone. Immunity against the foreign antigen may be established if a sufficient amount of the antigen can be introduced into the cytosol (Yewdell and Bennink, 1992, supra; Rock, 1996, Immunology Today 17: 131-137). This is the basis for development of *inter alia* cancer vaccines. One of the largest practical problems is to introduce sufficient amounts of antigens (or parts of the antigen) into the cytosol. This may be solved according to the present invention by PCI. This principle is illustrated in Fig.

- 11 -

1, which shows how PCI can be utilised to stimulate CTLs. A peptide or protein (P) is applied extracellularly to antigen-presenting cells. P is endocytosed and released into cytosol by PCI. The peptide or protein will thereafter be partly degraded by proteasomes and transported to the cells surface complexed to MHC (HLA) class I where the complex can be recognised by CTLs.

As will be described in more detail in the Examples below, it has been demonstrated that photochemical internalisation may be used efficiently according to the present invention for cytosolic delivery of cancer-specific peptides.

The antigenic molecule and/or photosensitivity agent may be targeted to specific cells or tissues by employing targeting agents e.g. target-specific delivery or carrier systems or carrier molecules. Thus for example the antigenic molecule and/or photosensitising agent may be delivered to the cell using a vector or carrier system e.g. reconstituted LDL-particles. The carrier molecule may be bound or conjugated to the antigenic molecule, to the photosensitising agent or both, and the same or different carrier molecules may be used. The antigenic molecule and/or photosensitising agent may also be conjugated to a site-targeting ligand, such as a ligand which is specific for particular cell-types or particular cell structures e.g. an antibody recognising a surface antigen expressed on certain cell types e.g. a tumour-specific antigen. Such mechanisms may act to increase uptake of the photosensitiser and/or antigen molecule through receptor-mediated endocytosis. Such targeting molecules carriers or vectors may also be used to direct the antigenic molecule and/or photosensitising agent to the intracellular compartment.

The intracellular membrane-restricted compartment may be any such compartment which is present in a cell. Preferably the compartment will be a membrane vesicle,

especially an endosome or a lysosome. However, the intracellular compartment may also include the Golgi apparatus or the endoplasmic reticulum. All that is required is that the antigenic molecule and the photosensitising agent locate to the same intracellular compartment(s).

The photochemical internalisation process is described in more detail in WO 96/07432 (the contents of which are incorporated herein by reference). Methods of PDT are also now widely described in the literature.

The photosensitizing agent to be used according to the present invention may be any such agent which localises to intracellular compartments, particularly endosomes or lysosomes. A range of such photosensitising agents are known in the art and are described in the literature, including in WO96/07432. Mention may be made in this respect of di- and tetrasulfonated aluminium phthalocyanine, sulfonated tetraphenylporphines (TPPS<sub>n</sub>), nile blue, chlorin e<sub>2</sub> derivatives, uroporphyrin I, phylloerythrin, hematoporphyrin and methylene blue which have been shown to locate in endosomes and lysosomes of cells in culture. This is in most cases due to endocytic activity.

Classes of suitable photosensitising agent which may be mentioned thus include porphyrins, phthalocyanines, purpurins, chlorins, benzoporphyrins naphthalocyanines, cationic dyes, tetracyclines and lysomotropic weak bases or derivatives thereof (Berg et al., Photochemistry and Photobiology, 1997, 65, 403-409).

Preferred photosensitising agents include TPPS<sub>2</sub>, (Zabner et al., J. Biol. Chem. 1995, 270, 18997-19007) TPPS<sub>3</sub> and AlPcS<sub>2</sub>.

The photochemical internalisation according to the present invention may be carried out using PDT methods which are known and standard in the art and appropriate

modifications of such techniques which are effective in this method. Thus, the antigenic molecule and photosensitising agent may be delivered to the cell by application or administration according to methods and means known in the art of PDT.

The methods of the present invention may be used *in vitro* or *in vivo*, either by *in situ* treatment or by *ex vivo* treatment, followed by administration of the treated cells.

Thus, a further aspect of the invention provides an antigen-presenting cell expressing an antigenic molecule, or a part thereof, on its surface, which cell is obtainable (or obtained) by a method as hereinbefore defined. Other aspects of the invention provide a population or culture of such cells, especially a viable and functionally intact population or culture of such cells, and also the use of such a cell (or population or culture of cells) in therapy, particularly for stimulating an immune response, and especially for stimulating CTLs.

Also provided is the use of such a cell (or population or culture of cells) for the preparation of a medicament (e.g. a vaccine composition) for stimulating an immune response, and especially for stimulating CTLs.

*In vivo*, any mode of administration common or standard in the art may be used, e.g. injection, infusion, topical administration, both to internal and external body surfaces etc. For *in vivo* use, the invention can be used in relation to any tissue which contains the target cells, including body fluid locations, as well as solid tissues. All tissues can be treated as long as the photosensitiser is taken up by the target cells, and the light can be properly delivered.

Thus, the compositions of the invention may be formulated in any convenient manner according to techniques and procedures known in the pharmaceutical

art, e.g. using one or more pharmaceutically acceptable carrier or excipients. The nature of the composition and carriers or excipient materials, dosages etc. may be selected in routine manner according to choice and the  
5 desired route of administration, purpose of vaccination etc. Dosages may likewise be determined in routine manner and may depend upon the nature of the antigenic molecule, purpose of vaccination, age of patient, mode of administration etc., in connection with the  
10 photosensitising agent the potency/ability to disrupt membranes on irradiation, should also be taken into account.

The light irradiation step to activate the photosensitising agent may likewise take place according  
15 to techniques and procedures well known in the art. For example, the wavelength and intensity of the light may be selected according to the photosensitising agent used. Suitable light sources are well known in the art.

As mentioned earlier, and as described in  
20 WO96/07432, it has been found that photochemical internalisation in this manner does not deleteriously affect the viability and functionality of the cells. In particular, it has been found that when a population or plurality of cells is treated according to the present  
25 invention, a majority of the cells are not killed, and survive the treatment, substantially functionally intact.

As used herein, the term "without killing the cell" is intended to define such a situation. In other words  
30 in a population or plurality of cells, substantially all of the cells, or a significant majority (e.g. at least 75%, more preferably at least 80, 85, 90 or 95% of the cells) are not killed.

Clearly when dealing with the light irradiation of  
35 a population or a plurality of cells it is possible that certain groups of cells or certain areas of tissue may receive more light or in some other way be subjected to



a larger PCI effect than other groups of cells or areas of tissue. Thus, the percentage values given for cell survival are not necessarily uniform across the entire irradiated population and refer to the percent of viable cells which remain in the irradiated population, the requirement being only that a sufficient portion of the irradiated cells survive. In addition, cell death induced by irradiation may take some time, e.g. a number of hours to occur. In this case it can be seen that cells which eventually die might also be able to express an antigenic molecule on their surface in accordance with the methods of the present invention and may thus be involved in the methods, uses etc. of the present invention. Thus the % cell death refers to the percent of cells which remain viable within a few hours of irradiation (e.g. up to 4 hours after irradiation) but preferably refers to the % viable cells 4 or more hours after irradiation.

The methods of the invention may be modified such that the fraction or proportion of the surviving cells is regulated by selecting the light dose in relation to the concentration of the photosensitivity agent. Again, such techniques are known in the art.

The present invention provides an efficient means for delivery of a large variety of antigenic molecules. The invention has a number of features rendering it particularly suitable as a vaccine delivery tool: 1) it has no restrictions on the size of the molecule to be delivered as long as the molecule can be endocytosed by the target cell; 2) it is not dependent on cell proliferation; 3) it is site specific in that only areas exposed to light are affected; 4) it is not oncogenic. In addition, photochemical internalisation may potentially be combined with other principles for generating site or tissue specific drug action, such as targeting by the use of specific ligands for cell surface structures, employing regulatory gene elements

- 16 -

that confer tissue specificity or the use of disease-specific drugs, opening a possibility of obtaining substantially synergistic effects in the specificity of drugs for target cells.

5       The invention will now be described in more detail in the following non-limiting Examples with reference to the following drawings in which:

10       Figure 1 shows a schematic representation of how PCI can be utilised to stimulate CTLs. A peptide or protein (P) is applied extracellularly to antigen presenting cells. P is endocytosed and released into cytosol by PCI. The peptide or protein will thereafter be partly degraded by proteasomes and transported to the cells surface complexed to MHC (HLA) class I where the  
15       complex can be recognised by CTLs.

20       Figure 2 shows photochemically induced relocalisation of a peptide. BL2-G-E6 cells were incubated with a fluorescein-labelled p21<sup>ras</sup>-derived 5-21, Val<sup>12</sup> peptide and AlPcS<sub>2a</sub>. The cells were examined for fluorescein-peptide and AlPcS<sub>2a</sub> localisation by  
25       fluorescence microscopy before (top panels) and 30 minutes after (bottom panels) a 4-min exposure to red light. Bar 20  $\mu$ m.

30       Figure 3 shows the cytotoxicity of a CD8<sup>+</sup> T lymphocyte clone against FM3 melanoma cells after PCI of a MART-1 peptide.

35       Figure 4 shows the ability of PCI to deliver HRP into the cytosol. NHIK 3025 cells were treated with 3.2  $\mu$ g/ml TPPS<sub>2a</sub> and 1 mg/ml HRP for 18 hours. The medium was then replaced with drug-free medium before exposure to the indicated light doses. HRP activity was measured in intact cells (○) and in cytosol (●) separated from cytosol-free cell corpses (▼) by electroporomeabilisation and a density centrifugation technique.

40       Figure 5 shows photochemically induced expression of GFP. a. expression of GFP in THX cells treated with pEGFP-N1-pLys complex in the absence of AlPcS<sub>2a</sub> and light

- 17 -

or in the presence of AlPcS<sub>2</sub>, followed by exposure to light as indicated on the figure. The cells were analysed by flow cytometry, reckoning the cells on the right side of the drawn line as positive for GFP expression. b. expression of GFP in THX cells treated for 18 hours with a photosensitiser (20 µg/ml AlPcS<sub>2a</sub> or 0.25 µg/ml 3-THPP) followed by a 6 hour transfection with pEGF-N1-pLys complex and exposure to light inactivating 50% of the cells. GFP expression was analysed by flow cytometry as described in a.

## EXAMPLES

### Materials and Methods

#### 5 Irradiation

Two different light sources were used for treatment of the cells, both consisting of a bank of 4 fluorescent tubes. Cells treated with TPPS<sub>4</sub>, TPPS<sub>2a</sub>, and 3-THPP (Porphyrin Products, Logan, UT) were exposed to blue light (model 3026; Appl. Photophysics, London, UK) with a light intensity reaching the cells of 1.5 mW/cm<sup>2</sup> while cells treated with AlPcS<sub>2a</sub> (Porphyrin Products, Logan, UT) were exposed to red light (Philips TL 20W/09) filtered through a Cinemoid 35 filter with a light intensity reaching the cells of 1.35 mW/cm<sup>2</sup>.

#### Fluorescence microscopy

20 The cells were analysed by fluorescence microscopy as described in Berg. K., et al., Biochem. Biophys. Acta., 1370: 317-324, 1998. For analysis of fluorescein-labelled molecules the microscope was equipped with a 450-490 nm excitation filter, a 510 nm dichroic beam splitter and a 510-540 nm band pass emission filter.

#### Preparation of Plasmid-pLys Complexes and Treatment of cells

30 Plasmid-pLys complexes (charge ratio, 1.7) were prepared by gently mixing 5 µg plasmid (pEGFP-N1; Clontech Laboratories, Inc., Palo Alto, CA) in 75 µl of HBS with 5.3 µg pLys (MW 20700; Sigma, St. Louis, MO) in 75 µl of HBS. The solutions were incubated for 30 min at room temperature, diluted with culture medium and added to the cells.

- 19 -

THX cells were incubated with 20  $\mu\text{g/ml}$   $\text{AlPcS}_{2a}$  for 18 hours at 37°C, washed and incubated in sensitizer-free medium for 3 hours before incubation with plasmid-pLys complexes for 2 hours. The pEGFP-N1/pLys treated THX cells were washed once and incubated for 2 hours in culture medium without additions before exposure to light. The cells were incubated at 37°C for 2 days, subcultured and further incubated for an additional 5 days before analysis of GFP expression by flow cytometry.

HCT-116 cells were incubated with 20  $\mu\text{g/ml}$   $\text{AlPcS}_{2a}$  for 18 hours, washed and transfected with plasmid-pLys complexes for 6 hours before light exposure in plasmid-free medium. After 40 hours incubation at 37°C the GFP expression was studied by microscopy.

#### Flow cytometry analysis

The cells were trypsinised, centrifuged, resuspended in 400  $\mu\text{l}$  of culture medium and filtered through a 50  $\mu\text{m}$  mesh nylon filter. The cells were then analysed in a FACStar plus flow cytometer (Becton Dickinson). Green Fluorescent Protein (GFP) was measured through a 510-530 nm filter after excitation with an argon laser (200 mW) tuned on 488 nm.  $\text{AlPcS}_{2a}$  was measured through a 650 nm longpass filter after excitation with a krypton laser (50 mW) tuned on 351-356 nm. Cell doublets were discriminated from single cells by gating on the pulse width of the GFP fluorescence signal. The data were analysed with PC Lysys II software (Becton Dickinson).

#### Preparation of Fluorescein-Peptide and Treatment of Cells

35

The fluorescein-labelled Val<sup>1</sup>-p21<sup>33</sup>-peptide (residues 5-21) were synthesised and provided by Alan Cuthbertson,

Nycomed Amersham).

BL2-G-E6 cells were incubated with 30  $\mu\text{g/ml}$  of the fluorescein-labelled p21<sup>ras</sup>-derived peptide for 18 hours followed by 20  $\mu\text{g/ml}$  AlPcS<sub>2a</sub> for 18 hours and 1 hour in drug-free medium before exposure to red light.

### Example 1

10 Photochemical internalisation (PCI) can be used to enable peptides to enter the cytosol of cells

To evaluate PCI for cytosolic delivery of cancer-specific peptides, a fluorescein-labelled p21<sup>ras</sup> peptide encompassing residues 5-21 and containing a Val<sup>12</sup> mutation (G12V) was used (Gjertsen, M.K., et al., Int. J. Cancer, 72: 784-790, 1997). In BL2-6-E6 mouse fibroblasts, the ras peptide colocalised well with AlPcS<sub>2a</sub>, indicating endocytic uptake of the peptide (Fig. 2). After a 4-min exposure to light, the fluorescein-labelled ras peptide and AlPcS<sub>2a</sub> were found to be located diffusely in the cytoplasm. Similar effects were not observed in cells exposed to the fluorescein-labelled ras peptide and light only (data not shown).

Example 2Use of PCI to induce antigen presentation and CD8<sup>+</sup> T lymphocyte mediated cell killing

5

FM3 melanoma cells ( $2 \times 10^5$ /well in 6 well plates), grown in RPMI 1640 medium with 10% foetal calf serum (FCS), not expressing MART-1 peptide were treated with 10  $\mu\text{g/ml}$  of the photosensitising agent  $\text{AlPcS}_2$  for 18 hours. The

10

cells were then released from the substratum with EDTA (0.1 M) in Dulbecco's phosphate-buffered saline (PBS) and kept in solution during loading of the cells with

$^{51}\text{Cr}$  (60  $\mu\text{Ci/ml}$   $\text{Na}_2\text{CrO}_4$ ) for 1 hour in 100% FCS followed by 5 hours incubation with 5  $\mu\text{g/ml}$  MART-1 peptide in

15

RPMI 1640 in 10% FCS, while the cells were still kept in solution. The sequence of the MART-1 peptide was:

TAEAAAGIGILTIVILG. The cells were then washed twice in RPMI 1640 medium containing 10% FCS and seeded out in

96-well plates (2000/well in 100  $\mu\text{l}$  medium (RPMI

20

1640/10% FCS). The cells were then exposed to light for the times as indicated in Figure 3 ((Philips TL 20W/09)

filtered through a Cinemoid 35 filter with a light intensity reaching the cells of 1.35  $\text{mW/cm}^2$  (Rodal et al., 1998, J. Photochem. Photobiol. B: Biol. 45: 150-

25

9)). 18 hours after light exposure the medium was removed and medium containing MART-1/HLA-A2 specific

cytotoxic T lymphocytes (CTLs - 40,000/well added in 100  $\mu\text{l}$ ) were added. After 4 hours of incubation the medium

was separated from FM3 cells and the  $^{51}\text{Cr}$  released to the medium (as an indicator of lysed cells) was counted as

30

well as the spontaneous and maximum release as

previously described (Fossum et al., 1995, Cancer Immunol. Immunother. 40: 165-172). The percentage

specific chromium release was calculated by the formula:

35

$(\text{experimental release} - \text{spontaneous release}) / (\text{maximum release} - \text{spontaneous release}) \times 100$ . It can be seen

from the results shown in Figure 3 that FM3 cells after

PCI of a MART-1 peptide as outlined above show light dependent susceptibility to CD8<sup>+</sup> T lymphocyte cytotoxicity.

5     Example 3

PCI induces the release of a large fraction of the endocytosed molecule

10    This was shown by PCI induced internalisation/ endocytosis of Horseradish Peroxidase (HRP).

By using HRP, it is demonstrated (see Figure 4) that PCI induces the release of a large fraction (>60%) of endocytosed HRP into the cytosol.

15    In this experiment NHIK 3025 cells (carcinoma cells in situ from human cervix) were treated with the photosensitising agent TPPS<sub>2a</sub> (3.2 µg/ml) and 1 mg/ml HRP for 18 hours. The medium was then replaced with drug free medium before exposure to the light doses as indicated in Figure 4. HRP activity was measured according to the procedure described in Steinman et al., J. Cell Biol., 68: 665-687, 1976. Cytosol was separated from cytosol-free cell corpses by

20    electropermeabilisation and a density centrifugation technique (Berg et al., Int. J. Cancer 59: 814-822, 1994).

30    Example 4

PCI can be used to enhance the delivery of functional genes

35    To demonstrate this, THX cells were transfected with a pLys-complex of a plasmid (pEGFP-N1) coding for green fluorescent protein (GFP). The expression of GFP was



analysed by flow cytometry (Fig. 5, a and b) and fluorescence microscopy (data not shown). As can be seen from Fig. 5a, treatment with  $\text{AlPcS}_{2a}$  and light led to a strong increase in the percentage of the cells expressing GFP. The fraction of the cells that was positive for this reporter molecule increased from 1% at no light treatment to 50% after a 5-min light exposure. GFP expression was not enhanced by light in cells treated with pEGFP-pLys in the absence of a photosensitiser. A complex of an irrelevant plasmid (encoding heme oxygenase) and pLys did not induce green fluorescence when combined with  $\text{AlPcS}_{2a}$  and light (data not shown). Consequently, in a light-directed manner, PCI can substantially increase the efficiency of transfection of a functional gene to THX cells. Similar results were obtained using  $\text{TPPS}_{2a}$  as a photosensitiser and BHK-21 and HCT-116 as target cells (data not shown). The essentially non-lysosomally located sensitiser 3-THPP induced only a minor increase in GFP expression (Fig. 5b). PCI of pEGFP-N1 not complexed with pLys did not induce the expression of GFP (data not shown).

Claims

1. A method of expressing an antigenic molecule or a part thereof on the surface of a cell, said method comprising introducing a molecule into the cell cytosol by photochemical internalisation, wherein said molecule, or a part thereof, is subsequently presented on the surface of said cell.
2. A method as claimed in claim 1, said method comprising:
- contacting said cell with said antigenic molecule or a part thereof and with a photosensitizing agent, wherein said molecule and said agent are each taken up into an intracellular membrane-restricted compartment of said cell; and
- irradiating said cell with light of a wavelength effective to activate the photosensitizing agent, such that the membrane of said intracellular compartment is disrupted, releasing said molecule into the cytosol of the cell, without killing the cell,
- wherein, said released antigenic molecule, or a part thereof, is subsequently presented on the surface of said cell.
3. The method of claim 1 or claim 2 wherein the antigenic molecule is a molecule capable of stimulating an immune response.
4. The method of claim 3 wherein the antigenic molecule is a vaccine antigen or vaccine component.
5. The method of any of the preceding claims wherein the antigenic molecule is a peptide.
6. The method of any of the preceding claims wherein the cell is an antigen presenting cell selected from the

- 25 -

group comprising lymphocytes, dendritic cells, macrophages and cancer cells.

7. The method of any of the preceding claims wherein the photosensitizing agent is selected from the group comprising porphyrins, phthalocyanines, purpurins, chlorins, benzoporphyrins naphthalocyanines, cationic dyes, tetracyclines and lysomotropic weak bases or derivatives thereof.

8. The method of claim 7 wherein the photosensitizing agent is TPPS<sub>4</sub>, TPPS<sub>2a</sub> or AlPCS<sub>2a</sub>.

9. The method of any of the preceding claims wherein the antigenic molecule and/or photosensitizing agent is bound to one or more targeting agents or carrier molecules.

10. The method of any of the preceding claims wherein said method is carried out *in vitro* or *in vivo*.

11. The method of any of the preceding claims wherein the antigenic presentation results in the stimulation of an immune response.

12. A method of vaccination comprising the method as defined in any one of the preceding claims.

13. A composition for use in expressing an antigenic molecule or a part thereof on the surface of a cell, said composition comprising an antigenic molecule as defined in any one of claims 1 to 5 or claim 9 and a photosensitizing agent as defined in any one of claims 2 or 7 to 9.

14. A cell expressing an antigenic molecule, or a part thereof, on its surface, or a population thereof, which

cell is obtainable by a method as defined in any one of claims 1 to 12.

15. A composition as defined in claim 13 or a cell  
5 population as defined in claim 14 for use in therapy.

16. Use of an antigenic molecule and a photosensitizing  
agent as defined in the preceding claims in the  
preparation of a medicament for use in expressing said  
10 antigenic molecule or a part thereof on the surface of a  
cell to stimulate an immune response or for stimulating  
CTLs.

17. Use of a cell population as defined in claim 14 for  
15 the preparation of a medicament for stimulating an  
immune response or for stimulating CTLs.

18. Use as claimed in claim 16 or claim 17 wherein said  
medicament is used in vaccination.

20  
19. Use as claimed in any one of claims 16 to 18  
wherein said medicament is used in the treatment of  
viral diseases, cancer or multiple sclerosis.

25  
20. A product comprising an antigenic molecule as  
defined in any one of claims 1 to 5 or claim 9 and a  
photosensitizing agent as defined in any one of claims 2  
or 7 to 9 as a combined preparation for simultaneous,  
separate or sequential use in expressing said antigenic  
30 molecule or a part thereof on the surface of a cell.

21. A kit for use in expressing an antigenic molecule  
or a part thereof on the surface of a cell, said kit  
comprising

35 a first container containing said antigenic  
molecule as defined in any one of claims 1 to 5 or claim  
9; and

- 27 -

a second container containing a photosensitizing agent as defined in any one of claims 2 or 7 to 9.



BEST AVAILABLE COPY

1 / 3




FIG. 1




FIG. 2

BEST AVAILABLE COPY

SUBSTITUTE SHEET (RULE 26)

2 / 3




FIG. 3




FIG. 4

SUBSTITUTE SHEET (RULE 26)

3 / 3





FIG. 5

BEST AVAILABLE COPY

SUBSTITUTE SHEET (RULE 26)